BPMC Stock Overview
A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Blueprint Medicines Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$89.54 |
| 52 Week High | US$121.90 |
| 52 Week Low | US$72.24 |
| Beta | 0.61 |
| 1 Month Change | -6.70% |
| 3 Month Change | 2.35% |
| 1 Year Change | 4.96% |
| 3 Year Change | 2.66% |
| 5 Year Change | 18.38% |
| Change since IPO | 374.51% |
Recent News & Updates
Recent updates
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Nov 24
Blueprint Medicines: Growth For The Long Term Still Mostly Priced In
Sep 27Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?
Aug 16Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S
Jul 23Blueprint Medicines: Overdue For A Breather
Jul 16Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 05Blueprint Medicines: Rampant Growth Mostly Priced In
May 04Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Apr 26Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Apr 05Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Shareholder Returns
| BPMC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.1% | 0.2% | -0.2% |
| 1Y | 5.0% | -4.7% | 25.8% |
Return vs Industry: BPMC exceeded the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: BPMC underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| BPMC volatility | |
|---|---|
| BPMC Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BPMC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BPMC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 638 | Kate Haviland | www.blueprintmedicines.com |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
Blueprint Medicines Corporation Fundamentals Summary
| BPMC fundamental statistics | |
|---|---|
| Market cap | US$5.61b |
| Earnings (TTM) | -US$128.05m |
| Revenue (TTM) | US$434.42m |
13.1x
P/S Ratio-44.4x
P/E RatioIs BPMC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPMC income statement (TTM) | |
|---|---|
| Revenue | US$434.42m |
| Cost of Revenue | US$12.93m |
| Gross Profit | US$421.48m |
| Other Expenses | US$549.53m |
| Earnings | -US$128.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.02 |
| Gross Margin | 97.02% |
| Net Profit Margin | -29.48% |
| Debt/Equity Ratio | 206.9% |
How did BPMC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 22:56 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Blueprint Medicines Corporation is covered by 32 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Ishan Majumdar | Baptista Research |
| Peter Lawson | Barclays |